Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Subjects With Chronic Stable Schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2014
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 07 Jul 2009 Actual end date (Jun 2009) and actual patient number (24) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.